The FDA skipped important approval checkpoints in order to get mifepristone, an abortion drug, on the market – regardless of how many women would get hurt. The FDA then did away with the requirement that drug providers report adverse affects in almost all cases. Clearly, this was not about women’s health. YAF has asked the Court to find the FDA violated its own rules.
Court: Supreme Court of the United States
Filed: February 29, 2024
Partner: Advancing American Freedom